SCHEMBL3869865

SCHEMBL3869865

CC(c1ccc(OCC(=O)Nc2ccc(-c3ccc(Cl)cc3)cc2)cc1)N1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.66
CHRM1 P11229 1/20 0.66
HTR2A P28223 1/20 0.66
ALDH1A1 P00352 5/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
TP53 P04637 3/20 0.54
THRB P10828 2/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.51
MAPT P10636 3/20 0.50
HTR2B P41595 1/20 0.49
KCNH2 Q12809 1/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3875635 0.85 MCHR1 (0.69) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL3872374 0.85 MCHR1 (0.57) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL3875628 0.84 MCHR1 (0.56) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL3869748 0.80 CHRM1 (0.98) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL4014334 0.79 CHRM1 (1.00) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL2610071 0.77 MEN1 (0.85) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL16082990 0.77 MEN1 (0.85) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL3868861 0.74 KMT2A (0.66) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL3868226 0.74 CHRM1 (0.74) MCHR1CHRM1HTR2AALDH1A1KMT2A
SCHEMBL25894434 0.74 MEN1 (0.78) MCHR1CHRM1HTR2AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R MCHR1 4/4885CHRM1 217/4885HTR2A 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.